T1000	Negation 4215 4218	not
E1000	Negation:T1000 Scope:T1001
T1001	Span 4215 4287	not affect the viability of the transgenic lymphocytes or lymphoma cells
T1002	Negation 4313 4316	not
E1001	Negation:T1002 Scope:T1003
T1003	Span 4305 4413	mTOR is not targeted by Akt activation in LMP1 transgenic lymphocytes or malignant lymphoma cells (Figure 7)
T1004	Negation 464 469	could
E1002	Negation:T1004 Scope:T1005
T1005	Span 464 503	could not be tested with the inhibitors
T1006	Negation 438 441	not
E1003	Negation:T1006 Scope:T1007
T1007	Span 438 459	not viable in culture
T1008	Negation 683 686	not
E1004	Negation:T1008 Scope:T1009
T1009	Span 683 741	not by treatment with rapamycin, U0126, or AG490 (Figure 7
T1010	Speculation 464 473	could not
E1005	Speculation:T1010 Scope:T1011
T1011	Span 464 503	could not be tested with the inhibitors
T1012	Negation 1371 1380	no longer
E1006	Negation:T1012 Scope:T1013
T1013	Span 1348 1400	phosphorylated Akt was no longer detected past 5 muM
T1014	Speculation 1006 1016	suggesting
E1007	Speculation:T1014 Scope:T1015
T1015	Span 1006 1140	suggesting that activation of Akt is required for the survival and growth of LMP1 transgenic lymphocytes and lymphoma cells (Figure 7)
T1016	Negation 2135 2144	no longer
E1008	Negation:T1016 Scope:T1017
T1017	Span 2135 2153	no longer detected
T1018	Speculation 1485 1492	suggest
E1009	Speculation:T1018 Scope:T1019
T1019	Span 1485 1646	suggest that triciribine specifically targets Akt and that Akt activation is required for the enhanced viability of the transgenic lymphocytes and lymphoma cells
T1020	Speculation 2179 2187	suggests
E1010	Speculation:T1020 Scope:T1021
T1021	Span 2179 2345	suggests that inhibition of NFkappaB can induce cell death in LMP1 transgenic lymphocytes and lymphoma cells without significant effects on activation of Akt or Stat3
T1022	Negation 2288 2295	without
E1011	Negation:T1022 Scope:T1023
T1023	Span 2288 2345	without significant effects on activation of Akt or Stat3
T1024	Negation 2997 2999	no
E1012	Negation:T1024 Scope:T1025
T1025	Span 2997 3107	no effect on growth (Figure 7), but activation of Akt, Stat3, or levels of IkappaBalpha were also not affected
T1026	Negation 2805 2808	not
E1013	Negation:T1026 Scope:T1027
T1027	Span 2805 2892	not detectable past 1 muM and at higher doses all protein levels were greatly decreased
T1028	Speculation 3135 3142	suggest
E1014	Speculation:T1028 Scope:T1029
T1029	Span 3135 3331	suggest that inhibition of Stat3 can induce cell death in LMP1 transgenic lymphocytes and lymphoma cells, but Stat3 inhibition also has considerable crossover effects on Akt and NFkappaB signaling
T1030	Negation 3095 3098	not
E1015	Negation:T1030 Scope:T1031
T1031	Span 3095 3107	not affected
T1032	Negation 3721 3724	not
E1016	Negation:T1032 Scope:T1033
T1033	Span 3721 3835	not significantly contribute to the enhanced viability in LMP1 transgenic lymphocytes or lymphoma cells (Figure 7)
T1034	Negation 3526 3529	not
E1017	Negation:T1034 Scope:T1035
T1035	Span 3526 3568	not U0126, an inhibitor of MEK1/2 activity
T1036	Negation 3987 3990	not
E1018	Negation:T1036 Scope:T1037
T1037	Span 3987 4026	not SB202190, AG490, or U0126 treatment
T1038	Speculation 3691 3701	suggesting
E1019	Speculation:T1038 Scope:T1039
T1039	Span 3691 3824	suggesting that p38 MAPK does not significantly contribute to the enhanced viability in LMP1 transgenic lymphocytes or lymphoma cells
T1040	Speculation 4028 4038	suggesting
E1020	Speculation:T1040 Scope:T1041
T1041	Span 4028 4095	suggesting that activation of Akt, NFkappaB, and Stat3 but not MAPK
T1042	Negation 4087 4090	not
E1021	Negation:T1042 Scope:T1043
T1043	Span 4087 4176	not MAPK pathways are characteristics associated with malignant transformation (Figure 7)
